IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trialOct 23Weekly roundup, 14 itemsabrocitinibatirmociclibUpdated
Pfizer registers real-world observational study of marstacimab in hemophilia A and B patientsOct 9Weekly roundup, 8 itemsabrocitinibcyclophosphamide
Pfizer recalls dopamine injection lot; two Phase 3 trials remain not yet recruitingSep 24Weekly roundup, 4 itemsdopaminePfizer
Pfizer posts MET097 obesity results; registers new Phase 3 obesity and dermatitis trialsAug 28Weekly roundup, 6 itemsberobenatidePF-08154225
FDA approves ZAVZPRET label update; Pfizer registers RSVpreF and prostate cancer studiesAug 21Weekly roundup, 7 itemsBioNTech SEPenbraya
Pfizer posts hemophilia results, opens eczema Phase 3, ends two skin studies earlyAug 14Weekly roundup, 6 itemsmarstacimab-hncqPF-06823859